Skip to main content

FDA Approvals

Hepzato Kit FDA Approved as a Liver-Directed Treatment for Uveal Melanoma With Hepatic Metastases

Gavreto Received Regular FDA Approval for Patients With Non–Small Cell Lung Cancer and RET Gene Fusion

Lonsurf Received a New Indication, in Combination With Bevacizumab, for Previously Treated Metastatic Colorectal Cancer

Jemperli Plus Chemotherapy Now FDA Approved for Front-Line Treatment of dMMR or MSI-H Endometrial Cancer

Vanflyta Now Approved for Newly Diagnosed FLT3-ITD–Positive AML

Talzenna Received a New Indication, With Enzalutamide, for Metastatic Castration-Resistant Prostate Cancer With HRR Gene Mutation

Nubeqa Now Indicated for Metastatic Hormone-Sensitive Prostate Cancer

Imfinzi Receives New FDA Indication for Advanced or Metastatic Biliary Tract Cancer

Retevmo Receives New FDA Indication for Advanced Solid Tumors with RET Fusion

Pemazyre Receives New Indication for FGFR1-Positive Myeloid/Lymphoid Neoplasms

Page 4 of 20
Results 31 - 40 of 200